Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Piper Sandler analyst Jason Bednar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $28.00.

According to Novocure, the Optune Lua system is now approved for use in combination with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (NSCLC ...

ROOT, Switzerland, October 01, 2024--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial ...

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale ...

From my colleague Adam Feuerstein: The FDA yesterday expanded the approval of Novocure’s Optune electrical ... with the entire health care system.

FDA approves NovoCure's Optune Lua for metastatic non-small cell lung cancer after platinum-based regimen. Optune Lua, combined with immunotherapy or docetaxel, extends overall survival by 3.3 months.

Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung ...